WO2022041123A1 - 倍半萜内酯类化合物在制备治疗视神经炎药物上的应用 - Google Patents

倍半萜内酯类化合物在制备治疗视神经炎药物上的应用 Download PDF

Info

Publication number
WO2022041123A1
WO2022041123A1 PCT/CN2020/112117 CN2020112117W WO2022041123A1 WO 2022041123 A1 WO2022041123 A1 WO 2022041123A1 CN 2020112117 W CN2020112117 W CN 2020112117W WO 2022041123 A1 WO2022041123 A1 WO 2022041123A1
Authority
WO
WIPO (PCT)
Prior art keywords
act001
optic neuritis
sesquiterpene lactone
application
group
Prior art date
Application number
PCT/CN2020/112117
Other languages
English (en)
French (fr)
Inventor
李洪恩
龚建苗
鲍世琦
张雪梅
Original Assignee
洛阳尚德药缘科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 洛阳尚德药缘科技有限公司 filed Critical 洛阳尚德药缘科技有限公司
Priority to EP20950793.8A priority Critical patent/EP4205738A4/en
Priority to PCT/CN2020/112117 priority patent/WO2022041123A1/zh
Priority to JP2023537447A priority patent/JP7579027B2/ja
Priority to US18/043,376 priority patent/US20230346742A1/en
Publication of WO2022041123A1 publication Critical patent/WO2022041123A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • the invention belongs to the medical field of autoimmune diseases, in particular to the application of a sesquiterpene lactone compound in preparing a medicine for treating optic neuritis.
  • NMO Neuromyelitis Optica
  • C-NMO-ON classic NMO-related optic neuritis
  • R-NMO-ON recurrent NMO-related optic neuritis
  • the visual function damage can be partially recovered, but the recovery gradually weakens with the increase of the number of episodes.
  • a considerable part of spinal cord damage in NMO occurs after vision loss, which can occur at intervals of days, weeks, months or even years, eventually leading to paraplegia, sensory and sphincter dysfunction, and in severe cases, respiratory muscle paralysis.
  • NMO a separate disease or multiple sclerosis (Multiple sclerosis)
  • MS multiple sclerosis
  • AQP4-Ab serum aquaporin 4 autoantibody
  • NMO neuronal apoptosis
  • the treatment of NMO mainly includes the treatment in the acute phase and the treatment in the remission phase.
  • the purpose of treatment in the acute phase is to minimize the dysfunction of the nervous system and promote the recovery of the disease.
  • it mainly includes high-dose methylprednisolone pulse therapy, plasma exchange, intravenous immunoglobulin and cyclophosphamide, etc.;
  • immunosuppressive agents including azathioprine, mycophenolate mofetil, mitoxantrone, methotrexate, rituximab and so on.
  • the existing treatment methods are widely used to suppress the immune system of the whole body and reduce the systemic autoimmune response.
  • the systemic side effects of patients are relatively large, and there is a risk of serious infection.
  • the treatment methods are easy to cause hormone tolerance and lead to treatment failure. .
  • the present invention through research, invents the application of a sesquiterpene lactone compound in preparing a medicine for treating optic neuritis.
  • optic neuritis is neuromyelitis optica.
  • Another preferred solution of the present invention is to prepare a medicament with a sesquiterpene lactone compound and a pharmaceutically acceptable auxiliary material.
  • the pharmaceutical agent is a liquid agent, a gas agent, a solid dosage form or a semi-solid dosage form.
  • Another preferred embodiment of the present invention is that the medicament is an injection.
  • Another preferred embodiment of the present invention is that the medicament is an oral medicament.
  • the oral preparation is a capsule.
  • Another preferred embodiment of the present invention is that the oral preparation is a pill.
  • sesquiterpene lactone compound is a smile lactone derivative.
  • the present invention uses the sesquiterpene lactone compound for the first time to prepare a medicine for treating optic neuritis, and the prepared medicine has a good curative effect especially in treating neuromyelitis optica.
  • Fig. 1 is the molecular formula of ACT001 described in the embodiment of the present invention.
  • FIG. 2 is a graph showing the results of the cytotoxicity test of ACT001 on BV-2 cells according to the embodiment of the present invention
  • FIG. 3 is a graph showing the release of TNF- ⁇ after ACT001 inhibits BV-2 being activated by LPS according to the embodiment of the present invention
  • FIG. 4 is a graph showing the release of IL-6 after ACT001 inhibits BV-2 being activated by LPS according to the embodiment of the present invention
  • 5 is a graph of NO release after ACT001 inhibits BV-2 being activated by LPS according to an embodiment of the present invention
  • FIG. 6 is a score chart of the ACT001 alleviation model of Lewis rat NMO disease symptoms according to the embodiment of the present invention.
  • the molecular formula of the sesquiterpene lactone compound studied in this example for preparing the drug for the treatment of neuromyelitis optica is shown in Figure 1, also known as ACT001, and the chemical name of ACT001 is: (3R, 3aS, 9R, 9aS, 9bS) -3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazulo[4, 5-b] Furan-2(9bH)-one fumarate, a laugholide derivative.
  • the molecular formula is shown in Figure 1. This example uses ACT001 to conduct a treatment study on AQP4 autoimmune antibody-positive neuromyelitis optica patients.
  • ACT001 can inhibit the proliferation of BV-2 cells in vitro, and its IC50 value is 23.6 ⁇ M. And it can significantly reduce the release of microglial inflammatory factors (TNF- ⁇ , IL-6, NO) activated by LPS at 10 ⁇ M, and reduce the inflammatory response of microglial cells.
  • TNF- ⁇ , IL-6, NO microglial inflammatory factors
  • Lewis rats were firstly subjected to spinal cord intrathecal cannulation surgery, which can control the length of the PE10 hose (7cm) and place the outlet at the first segment of the lumbar vertebra of the rat spinal cord. Lewis rats after spinal cord intrathecal cannulation. On the second day after the operation, the behavior of the rats was the same as that of normal rats.
  • the successfully modeled rats were divided into three groups, and 10 ⁇ L of NMO patient serum and complement system were injected into the flexible tube of the successfully intubated rats. , every four days, replenish once.
  • the dosing schedule was as follows: 6 animals in the model control group were intragastrically administered with normal saline for 15 consecutive days; 8 animals in the hormone group were intragastrically administered with methylprednisolone amber solution for injection daily at a dose of 30 mg/kg for consecutive 15 days. On the 15th; 6 animals in the ACT001 group were given ACT001 solution by gavage every day at a dose of 60 mg/kg for 15 consecutive days. Animal status was observed every day, and behavioral scores were recorded according to animal symptoms. The results showed that the animals in the ACT001 group tolerated well, and the disease symptoms were significantly relieved compared with the normal saline control group. Compared with the hormone treatment group, the ACT001 group had a similar remission effect, and the comprehensive score was basically the same.
  • ACT001 can effectively inhibit the inflammatory response of microglia, and can significantly reduce the release of inflammatory factors including NO, TNF- ⁇ , and IL-6.
  • ACT001 could inhibit the proliferation of BV2 cells in vitro.
  • the IC 50 value of ACT001 on BV2 cells was 23.6 ⁇ 2.34 ⁇ M , see Table 1 and Figure 2.
  • BV2 cells were digested, counted, seeded in 24-well plates, 1 ml per well, 20,000 cells, and cultured overnight in a 5% CO2, 37°C incubator. 1 ⁇ g/mL LPS was added to all wells for 1 hour, and then different concentrations of ACT001 were added.
  • Five experimental groups were set up, namely: 1control group; 2ACT001-2.5 ⁇ M group; 3ACT001-5 ⁇ M group; 4ACT001-10 ⁇ M group; 5ACT001-20 The ⁇ M group was treated for 8 h. After the drug effect was over, the supernatant was collected, centrifuged at 12000 rpm for 20 min, and ELISA was performed according to the instructions of the kit.
  • Figure 2 is a graph showing the effect of ACT001 on the proliferation activity of BV2 cells. It can be seen from Figure 2 that, compared with the control group, the ACT001 group can reduce the expression of IL-6 in BV-2 cells, and with the increase of the dose of ACT001, its inhibitory effect The enhancement was dose-dependent. The p-values of the ACT001 10 ⁇ M and 20 ⁇ M dose groups were both less than 0.001 compared with the control group, that is, extremely significantly reduced, and the trend was consistent among the three replicates.
  • BV2 cells were digested, counted, seeded in 24-well plates, 1 ml per well, 40,000 cells, and cultured overnight in a 5% CO 2 incubator at 37°C. 1 ⁇ g/ml LPS was added to all wells for 1 h, and then different concentrations of ACT001 were added to set up five experimental groups: 1control group; 2ACT001-2.5 ⁇ M group; 3ACT001-5 ⁇ M group; 4ACT001-10 ⁇ M group; 5ACT001-20 ⁇ M group The group was treated for 24 h. After the drug effect was over, the supernatant was collected, centrifuged at 12,000 rpm for 20 min, and ELISA was performed according to the instructions of the kit.
  • Figure 3 shows the effect of ACT001 on the expression of IL-6 ( *P ⁇ 0.05 , **P ⁇ 0.01 , ***P ⁇ 0.001 ). It can be seen from Figure 3 that compared with the control group, the ACT001 group can reduce BV-2 The expression of TNF ⁇ in cells, and its inhibitory effect was enhanced with the increase of the dose of ACT001, in a dose-dependent manner. Compared with the control group, the p value of the ACT001 dose group was less than 0.001, that is, it was extremely significantly reduced, and the trend of the three repetitions was consistent.
  • BV2 cells were digested, counted, seeded in 24-well plates, 1 ml per well, 40,000 cells, and cultured overnight in a 5% CO 2 incubator at 37°C. 1 ⁇ g/mL LPS was added to all wells for 1 h, and then different concentrations of ACT001 were added to set up five experimental groups: 1control group; 2ACT001-2.5 ⁇ M group; 3ACT001-5 ⁇ M group; 4ACT001-10 ⁇ M group; 5ACT001-20 ⁇ M group The group was treated for 24 h. After the drug effect was over, the supernatant was collected, centrifuged at 12,000 rpm for 20 min, and ELISA was performed according to the instructions of the kit.
  • Figure 4 shows the effect of ACT001 on the expression of TNF ⁇ ( *P ⁇ 0.05 , **P ⁇ 0.01 , ***P ⁇ 0.001 ). It can be seen from Figure 4 that compared with the control group, the ACT001 2.5, 5, and 10 ⁇ M dose groups can all It reduces the expression of NO in BV-2 cells, and its inhibitory effect is enhanced with the increase of ACT001 dose in a dose-dependent manner, and the ACT001 10 ⁇ M dose group is significantly lower than the control group.
  • Figure 5 is a graph of the effect of ACT001 on NO expression ( *P ⁇ 0.05 , **P ⁇ 0.01 , ***P ⁇ 0.001 ). As shown in Figure 5, ACT001 can significantly reduce microglia at a concentration of 5 ⁇ M Pathological release of cellular NO.
  • the dose of group B is equivalent to the dosage of ACT001 given to the human body after ACT001 and pharmaceutically acceptable excipients are made into a drug
  • the dose of group C is equivalent to the dose of ACT001 and pharmaceutically acceptable excipients.
  • the dosage of ACT001 in humans is about 10 mg/kg.
  • the scoring criteria are as follows:
  • Figure 6 is an animal model behavioral score. According to Table 2 and Figure 6, it can be seen that ACT001 can significantly reduce the behavioral score of the NMO animal model, improve the symptoms of the NMO disease model, and the effect is not weaker than that of hormones.
  • Table 3 is the in vivo pharmacodynamic test
  • ACT001 has significant advantages in the treatment of NMO.
  • the IC50 value of ACT001 on BV-2 microglia was measured to be 23.6 ⁇ M, and it can significantly reduce the release of inflammatory factors including NO, TNF- ⁇ and IL-6, thereby inhibiting the Microglial inflammatory response triggered by LPS stimulation.
  • ACT001 could significantly relieve the clinical symptoms of the animal model of neuromyelitis optica.
  • the behavioral score of the saline control group was 3.17 ⁇ 0.26, while the behavioral score of the ACT001 group was 3.17 ⁇ 0.26.
  • the ACT001 score was 2.00 ⁇ 0.32, which was basically the same as the behavioral score of the hormone group, which was 2.31 ⁇ 0.26. It shows that ACT001 can replace hormones and become a new treatment method for NMO disease in clinical practice.
  • ACT001 Our first choice is ACT001.
  • the derivatives and their salts of laugholide also have the effect of treating neuromyelitis optica.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种倍半萜内酯类化合物在制备治疗视神经炎药物上的应用，将倍半萜内酯类化合物与医药上可接受的辅料制备成药剂。本研究发现，ACT001可有效抑制小胶质细胞的炎性反应，能够显著降低包括NO、TNF-α、IL-6在内的炎性因子的释放。有抑制BV2细胞增殖的作用。对视神经炎，尤其是视神经脊髓炎有很好的疗效。

Description

倍半萜内酯类化合物在制备治疗视神经炎药物上的应用 技术领域
本发明属于自身免疫性疾病的医药领域，具体涉及倍半萜内酯类化合物在制备治疗视神经炎药物上的应用。
 背景技术
视神经脊髓炎（Neuromyelitis Optica, NMO）是一种累及视神经和脊髓的脱髓鞘疾病。该疾病最早的报道见于 1872 年，最初被认为是一种单病程发病的中枢神经系统病变。在亚洲国家，关于NMO的报道较多，仅在我国，目前就有超过30万的NMO患者。在神经眼科门诊，经典NMO 相关的视神经炎（C-NMO-ON）主要表现为双眼同时或相继发病，视力下降迅速，可伴有或不伴有眼痛；视功能恢复较差，通常会遗留双眼或至少一眼的严重视力障碍。而复发性 NMO 相关的视神经炎（R-NMO-ON）多为单眼发病，易复发，视功能损害可部分恢复但随着发病次数增加恢复逐渐减弱。相当一部分NMO的脊髓损害发生在视力下降之后，可间隔数天、数周、数月甚至数年，最终导致截瘫、感觉及括约肌功能障碍，重者可致呼吸肌麻痹。由于复发性NMO在初期临床表现上与复发性视神经炎有许多共同特点，因此极易被误诊为后者，这一方面延误了治疗时机，另一方面视神经炎的治疗手段会加重NMO的病情，造成更严重的后果。
在很长一段时间，对NMO是独立的疾病还是多发硬化症(Multiple Sclerosis,MS)的亚型一直存在着争议，近些年的研究发现血清中水通道蛋白4（Aquaporin 4,AQP4）自身抗体(AQP4-Ab)是NMO诊断中非常特异的一项指标，在NMO诊断中有较高的敏感性（68-91%）和特异性（85-99%）。
NMO 的特殊性是由于其特殊的发病机制造成的。进一步的研究表明，AQP4-Ab和中枢神经系统(Central nervous system，CNS)中的星形胶质细胞终足上的水通道蛋白 4（ aquaporin 4,AQP4）有着特异性的结合。目前已知AQP4-Ab对星形胶质细胞的伤害作用可以通过补体依赖的细胞毒性和抗体依赖的细胞毒性两种途径来实现。根据Verkman 研究团队的最新报道，向脑实质中注射AQP4-Ab能引起NMO 样的组织病变。具体病理改变包括：星形胶质细胞损伤、少突胶质细胞减少、髓鞘丢失以及神经元凋亡。这种现象与患者体内发生的病理变化有部分相似之处，因此可以用来研究 NMO 发病过程中在细胞水平上的致病机制。目前关于 NMO 的致病机制较为一致的观点是 AQP4-Ab先造成了星形胶质细胞的死亡，然后才引起了脱髓鞘病变，在这个过程中伴随小胶质细胞的异常激活，释放大量炎性因子，形成NMO疾病炎性致病微环境。围绕AQP4的研究及AQP4-Ab的发现，才最终将NMO从多发硬化症中分离出来。
 技术问题
目前NMO的治疗主要包括急性期的治疗和缓解期的治疗。急性期治疗的目的在于尽量减少神经系统功能障碍并促进疾病的恢复，目前主要包括大剂量甲泼尼龙冲击治疗、血浆置换、静脉注射免疫球蛋白及环磷酰胺等；缓解期治疗的目的主要在于减少疾病复发的次数及减轻复发的严重性，主要为免疫抑制剂的应用，包括硫唑嘌呤、吗替麦考酚酯、米托蒽醌、甲氨蝶呤、利妥昔单抗等等。但是，目前现有的治疗手段均是广泛的抑制全身的免疫系统，减轻全身自身免疫反应，患者的全身副作用较大，有引发严重感染的风险，且治疗方法容易引发激素耐受从而导致治疗失效。
因此，NMO严重缺乏安全有效的药物，临床需求未能满足，研发治疗该疾病的新药，需求非常迫切。
 技术解决方案
本发明为解决现有技术中的上述问题，通过研究，发明了一种倍半萜内酯类化合物在制备治疗视神经炎药物上的应用。
本发明的另一优选方案是，所述视神经炎为视神经脊髓炎。
本发明的另一优选方案是，将倍半萜内酯类化合物与医药上可接受的辅料制备成药剂。
本发明的另一优选方案是，所述药剂为液体剂、气体剂、固体剂型或半固体剂。
本发明的另一优选方案是，所述药剂为注射剂。
本发明的另一优选方案是，所述药剂为口服剂。
本发明的另一优选方案是，所述口服剂为胶囊剂。
本发明的另一优选方案是，所述口服剂为丸剂。
本发明的另一优选方案是，所述倍半萜内酯类化合物为含笑内酯衍生物。
 有益效果
本发明首次将倍半萜内酯类化合物用于制备治疗视神经炎的药物，所制备药物尤其在治疗视神经脊髓炎方面有很好的疗效。
 附图说明
图1是本发明实施例所述的ACT001分子式；
图2是本发明实施例所述的ACT001对BV-2细胞细胞毒性实验结果图；
图3是本发明实施例所述的ACT001抑制BV-2被LPS激活后TNF-α释放图；
图4是本发明实施例所述的ACT001抑制BV-2被LPS激活后IL-6释放图；
图5是本发明实施例所述的ACT001抑制BV-2被LPS激活后NO释放图；
图6是本发明实施例所述的ACT001缓解Lewis大鼠NMO疾病症状模型评分图。
 本发明的最佳实施方式
下面结合附图对本发明进行详细描述，本部分的描述仅是示范性和解释性，不应对本发明的保护范围有任何的限制作用。此外，本领域技术人员根据本文件的描述，可以对本文件中实施例中以及不同实施例中的特征进行相应组合。
实施例1
本实施例所研究的用于制备治疗视神经脊髓炎药物的倍半萜内酯类化合物分子式如图1所示，又称为ACT001，ACT001化学名称为：(3R,3aS,9R,9aS,9bS)-3-((二甲基胺基)甲基)-9-羟基-6,9-二甲基-3,3a,4,5,7,8,9,9a-八氢化薁并[4,5-b]呋喃-2(9bH)-酮富马酸盐，是一种含笑内酯衍生物。分子式如图1所示。本实施例使用ACT001对AQP4自身免疫性抗体阳性视神经脊髓炎患者进行治疗研究。
药理药效实验如下：
1、我们首先对活性成分进行了体外试验，根据体外试验结果显示，ACT001在体外可抑制BV-2细胞的增殖，其IC50值为23. 6μM。并且能够在10μM 显著降低被LPS激活的小胶质细胞炎性因子（TNF-α，IL-6，NO）的释放，降低小胶质细胞炎性反应。
同时，在建立NMO动物模型前，首先对Lewis大鼠行脊髓鞘内置管手术，该手术可通过控制PE10软管的长度（7cm），将出口置于大鼠脊髓腰椎第一节的位置。脊髓鞘内置管术术后的Lewis大鼠。手术后第二天，大鼠行动与正常大鼠无异，将建模成功的大鼠分为三组，把NMO患者血清以及补体系统各10μL注射入插管成功后的大鼠的软管中，每隔四天，补充一次。给药方案为，模型对照组6只动物每日灌胃给与生理盐水，连续15日；激素组8只动物，每日灌胃给予注射用甲泼尼龙琥珀溶液，剂量为30mg/kg，连续15日；ACT001组6只动物，每日灌胃给予ACT001溶液，剂量为60mg/kg，连续15日。每天观察动物状态，根据动物症状记录行为学评分。结果显示，ACT001组动物耐受良好，相比生理盐水对照组，疾病症状得到显著缓解，ACT001组与激素治疗组相比，缓解效果类似，综合评分基本持平。
然后我们拟将ACT001用于治疗视神经脊髓炎。ACT001可有效抑制小胶质细胞的炎性反应，能够显著降低包括NO、TNF-α、IL-6在内的炎性因子的释放。我们首先应用体外MTT法、CCK8法评价ACT001对小胶质细胞BV2增殖活性的影响，结果表明ACT001体外有抑制BV2细胞增殖的作用，具体表现为ACT001对BV2细胞的IC 50值为23.6±2.34μM，见表1、图2。
Figure 89849dest_path_image001
 2、ACT001对BV2细胞体外活性抑制作用
BV2细胞消化，计数，接种于24孔板，每孔1ml，20000个细胞，5% CO2、37℃培养箱培养过夜。所有孔加入1µg/mL LPS作用1h后加入不同浓度的ACT001，设置五个实验组，分别为：①control组；②ACT001-2.5 μM组；③ACT001-5 μM组；④ACT001-10 μM组；⑤ACT001-20 μM组，作用8h，药物作用结束后，收集上清，12000rpm离心20min，按照试剂盒说明步骤进行ELISA。
图2是ACT001对BV2细胞增殖活性影响图，由图2可知，与对照组相比，ACT001组均能降低BV-2细胞中IL-6的表达，且随ACT001作用剂量的增加对其抑制作用增强，具有剂量依赖性，ACT001 10µM和20µM剂量组较对照组p值均小于0.001，即极为显著降低，三次重复趋势一致。
3、ACT001对IL-6表达的影响
BV2细胞消化，计数，接种24孔板，每孔1ml，40000个细胞，5% CO 2、37℃培养箱培养过夜。所有孔加入1µg/ml LPS作用1h后加入不同浓度的ACT001，设置五个实验组，分别为：①control组；②ACT001-2.5 μM组；③ACT001-5 μM组；④ACT001-10 μM组；⑤ACT001-20 μM组，作用24h，药物作用结束后，收集上清，12000 rpm离心20 min，按照试剂盒说明步骤进行ELISA。
图3 为 ACT001对IL-6表达的影响（ *P<0.05 ， ** P<0.01 ， *** P<0.001），由图3可知，与对照组相比，ACT001组均能降低BV-2细胞中TNFα的表达，且随ACT001作用剂量的增加对其抑制作用增强，具有剂量依赖性，ACT001剂量组较对照组p值均小于0.001，即极为显著降低，三次重复趋势一致。
4、ACT001对TNFα表达的影响
BV2细胞消化，计数，接种24孔板，每孔1ml，40000个细胞，5% CO 2、37℃培养箱培养过夜。所有孔加入1µg/mL LPS作用1h后加入不同浓度的ACT001，设置五个实验组，分别为：①control组；②ACT001-2.5 μM组；③ACT001-5 μM组；④ACT001-10 μM组；⑤ACT001-20 μM组，作用24 h，药物作用结束后，收集上清，12000 rpm离心20 min，按照试剂盒说明步骤进行ELISA。   
图4是 ACT001对TNFα表达的影响（ *P<0.05 ， ** P<0.01 ， *** P<0.001），由图4可知，与对照组相比，ACT001 2.5、5、10µM剂量组均能降低BV-2细胞中NO的表达，且随ACT001作用剂量的增加对其抑制作用增强，具有剂量依赖性，其中ACT001 10µM剂量组较对照组极为显著降低。
5、图5是ACT001对NO表达的影响图（ *P<0.05 ， ** P<0.01 ， *** P<0.001），由图5所知， ACT001在5μM浓度下即可显著降低小胶质细胞NO的病理性释放。
6、ACT001对NMO患者体外试验和动物模型的作用
将NMO患者的血清及补体系统各10μL注射入进行脊髓鞘内置管手术成功的大鼠软管中，每隔四天，补充一次，建立NMO动物模型。将模型动物随机分为三组：生理盐水组、激素（注射用甲泼尼龙琥珀酸钠）组及ACT001组，给药方案如下：
Figure 994351dest_path_image002
即，B组剂量相当于ACT001与药学上可接受的辅料制成药剂后给予人体的给药量ACT001约5mg/kg ，C组组剂量相当于ACT001与药学上可接受的辅料制成药剂后给予人体的给药量ACT001约10mg/kg。
根据动物症状进行行为学评分。
评分标准如下：
0 分：无临床症状；
    1 分：尾部张力降低或轻度步态笨拙；
    2 分：尾部无张力或中度步态异常；双后肢无力，被动翻身后可以恢复；
    3 分：双后肢瘫痪。被动翻身后不能恢复，但给予刺激后可以挪动；
    4 分：双后肢瘫痪。前肢瘫痪或肌力减弱并有尿便失禁；
    5 分：濒死状态或死亡。
    症状处于两者标准之间者以±0.5计。
实验结果表明，给药期间，ACT001组动物耐受良好，相比生理盐水对照组，疾病症状得到显著缓解，ACT001组与激素治疗组相比，缓解效果类似，行为学评分基本持平。实验结果如表2和图6所示：
表2 各组动物行为学评分
Figure 31577dest_path_image003
注：与生理盐水比较， *P<0.05 ， ** P<0.01 ， *** P<0.001
图6是 动物模型行为学评分。根据表2和图6可以看出ACT001能够显著降低NMO动物模型行为学评分，改善NMO疾病模型症状，并且作用效果不弱于激素。
表3是体内药效学试验
Figure 513374dest_path_image004
Figure 300939dest_path_image005
由上述结果可以看出，在治疗NMO方面，ACT001具有显著优势。通过开展ACT001体外活性测试，测得ACT001对BV-2小胶质细胞的IC50值为23.6μM，且可显著降低NO、TNF-α、IL-6在内的炎性因子的释放，从而抑制由LPS刺激引发的小胶质细胞炎性反应。
在视神经脊髓炎的动物模型中，通过实验结果发现ACT001能够显著缓解视神经脊髓炎动物模型的临床症状，连续给药15天，生理盐水照组的行为学评分为3.17±0.26，而ACT001组的行为学评分为2.00±0.32，相较于激素组的行为学评分2.31±0.26，ACT001与其基本持平。说明ACT001可以替代激素成为临床上NMO疾病的一种全新的治疗方式。
我们首选ACT001，除ACT001外，我们按照上述实验，含笑内酯的衍生物及其盐也具有能够治疗视神经脊髓炎的作用。
上述实施例为本发明较佳的实施方式，但本发明的实施方式并不受上述实施例的限制，其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化，均应为等效的置换方式，都包含在本发明的保护范围之内。

Claims (7)

  1. 一种如下分子式的倍半萜内酯类化合物在制备治疗视神经炎药物上的应用：
    Figure 377437dest_path_image001
    。
  2. 根据权利要求1所述倍半萜内酯类化合物在制备治疗视神经炎药物上的应用，其特征是，所述视神经炎为视神经脊髓炎。
  3. 根据权利要求1所述倍半萜内酯类化合物在制备治疗视神经炎药物上的应用，其特征是，所述视神经炎为视神经脊髓炎。
  4. 根据权利要求1所述倍半萜内酯类化合物在制备治疗视神经炎药物上的应用，其特征是，所述药剂为液体剂、气体剂、固体剂型或半固体剂。
  5. 根据权利要求4所述倍半萜内酯类化合物在制备治疗视神经炎药物上的应用，其特征是，所述药剂为注射剂。
  6. 根据权利要求4所述倍半萜内酯类化合物在制备治疗视神经炎药物上的应用，其特征是，所述药剂为口服剂。
  7. 根据权利要求1-6任意一项权利要求所述倍半萜内酯类化合物在制备治疗视神经炎药物上的应用，其特征是，所述倍半萜内酯类化合物为含笑内酯衍生物。
PCT/CN2020/112117 2020-08-28 2020-08-28 倍半萜内酯类化合物在制备治疗视神经炎药物上的应用 WO2022041123A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP20950793.8A EP4205738A4 (en) 2020-08-28 2020-08-28 USE OF SESQUITERPEN LACTONE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OPTICAL NEURITIS
PCT/CN2020/112117 WO2022041123A1 (zh) 2020-08-28 2020-08-28 倍半萜内酯类化合物在制备治疗视神经炎药物上的应用
JP2023537447A JP7579027B2 (ja) 2020-08-28 セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用
US18/043,376 US20230346742A1 (en) 2020-08-28 2020-08-28 Application of sesquiterpene lactone in preparing drug for treating optic neuritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/112117 WO2022041123A1 (zh) 2020-08-28 2020-08-28 倍半萜内酯类化合物在制备治疗视神经炎药物上的应用

Publications (1)

Publication Number Publication Date
WO2022041123A1 true WO2022041123A1 (zh) 2022-03-03

Family

ID=80352485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/112117 WO2022041123A1 (zh) 2020-08-28 2020-08-28 倍半萜内酯类化合物在制备治疗视神经炎药物上的应用

Country Status (3)

Country Link
US (1) US20230346742A1 (zh)
EP (1) EP4205738A4 (zh)
WO (1) WO2022041123A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3320901A1 (en) * 2016-01-28 2018-05-16 Tianjin International Joint Academy of Biotechnology & Medicine Application of dimethylamino micheliolide
CN109897022A (zh) * 2017-12-07 2019-06-18 中国医学科学院药物研究所 含笑内酯衍生物、其药物组合物及其制备方法和用途
US20190314324A1 (en) * 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
CN111494366A (zh) * 2019-01-31 2020-08-07 洛阳尚德药缘科技有限公司 二甲基氨基含笑内酯在制备抗衰老药物上的应用
CN111743894A (zh) * 2019-03-28 2020-10-09 洛阳尚德药缘科技有限公司 倍半萜内酯类化合物在制备治疗视神经炎药物上的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3320901A1 (en) * 2016-01-28 2018-05-16 Tianjin International Joint Academy of Biotechnology & Medicine Application of dimethylamino micheliolide
CN109897022A (zh) * 2017-12-07 2019-06-18 中国医学科学院药物研究所 含笑内酯衍生物、其药物组合物及其制备方法和用途
US20190314324A1 (en) * 2018-04-13 2019-10-17 The University Of Chicago Combination of micheliolide derivatives or nanoparticles with ionizing radiation and checkpoint inhibitors for cancer therapy
CN111494366A (zh) * 2019-01-31 2020-08-07 洛阳尚德药缘科技有限公司 二甲基氨基含笑内酯在制备抗衰老药物上的应用
CN111743894A (zh) * 2019-03-28 2020-10-09 洛阳尚德药缘科技有限公司 倍半萜内酯类化合物在制备治疗视神经炎药物上的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEVIN, M.H. ET AL.: "Optic neuritis in neuromyelitis optica", PROGRESS IN RETINAL AND EYE RESEARCH, vol. 36, 30 March 2013 (2013-03-30), pages 159 - 171, XP028703475, DOI: 10.1016/j.preteyeres.2013.03.001 *
LI, Q.Y. ET AL.: "ACT001 modulates the NF-KB/MnSOD/ROS axis by targeting IKKbeta to inhibit glioblastoma cell growth", JOURNAL OF MOLECULAR MEDICINE, vol. 98, 4 January 2020 (2020-01-04), pages 263 - 277, XP037014878, DOI: 10.1007/s00109-019-01839-0 *
QIN XIANGYANG, JIANG XINRU, JIANG XIN, WANG YULI, MIAO ZHULEI, HE WEIGANG, YANG GUIZHEN, LV ZHENHUI, YU YIZHI, ZHENG YUEJUAN: "Micheliolide inhibits LPS-induced inflammatory response and protects mice from LPS challenge", SCIENTIFIC REPORTS, vol. 6, no. 1, 1 September 2016 (2016-09-01), XP055904432, DOI: 10.1038/srep23240 *
See also references of EP4205738A4 *

Also Published As

Publication number Publication date
EP4205738A1 (en) 2023-07-05
US20230346742A1 (en) 2023-11-02
EP4205738A4 (en) 2024-05-01
JP2023539391A (ja) 2023-09-13

Similar Documents

Publication Publication Date Title
EP3064206B1 (en) Treatment of huntington&#39;s disease using laquinimod
AU2013295370B2 (en) Use of biotin for the treatment of multiple sclerosis
US20040077591A1 (en) Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer&#39;s Disease
US20180235934A1 (en) Noradrenergic drug treatment of obstructive sleep apnea
JP2015512406A (ja) ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療
KR20120050473A (ko) 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도
JPH06329541A (ja) 糖尿病性腎症治療用スロデキサイド含有医薬
JP2019533731A (ja) Ｃｂｄとコパキソンの併用療法
WO2022041123A1 (zh) 倍半萜内酯类化合物在制备治疗视神经炎药物上的应用
WO1998046226A1 (en) Method for treating schizophrenia
JP2018515447A (ja) 軸索障害の処置用のパルテノライドおよびその誘導体
JP7579027B2 (ja) セスキテルペンラクトン系化合物の視神経炎治療薬の製造における使用
CN111743894A (zh) 倍半萜内酯类化合物在制备治疗视神经炎药物上的应用
Cook et al. Hypertensive crisis precipitated by a monoamine oxidase inhibitor in a patient with phaeochromocytoma.
Stolarek et al. Acute dystonia induced by midazolam and abolished by flumazenil.
RU2564907C1 (ru) Способ лечения больных красным плоским лишаем
JPH0410445B2 (zh)
CN112891338B (zh) 倍半萜内酯类化合物在制备治疗mog抗体阳性视神经炎药物上的应用
WO2018220457A1 (en) Vitamin b1 in high doses for use in the medical treatment of motor symptoms of some sporadic neurodegenerative diseases, of genetic origin, and of cluster headache and of migraine headache
US20040048871A1 (en) Use of high dose intravenous methotrexate, with leucovorin rescue, to treat early multiple sclerosis and other diseases of the central nervous system
Bain et al. The treatment of essential hypertension with pentolinium tartrate combined with Rauwolfia alkaloids
CN112972448B (zh) 贝利司他在制备预防、缓解和/或治疗多发性硬化症药物中的应用
US20170196987A1 (en) Methods for treating multiple sclerosis
WO2024033946A1 (en) Compositions and use in methods for treating a cognitive deficit
WO2019135363A1 (ja) 腱滑膜病変を主体とした疾患の治療薬

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20950793

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023537447

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020950793

Country of ref document: EP

Effective date: 20230328